Daniella Kranjac Mesa Panel Featured in Gen Eng News

Featured in Genetic Engineering & Biotechnology News news the article summarized an exciting panel Founding Partner, Daniella Kranjac, participated in at the annual Cell and Gene on the Mesa presented by the Alliance for Regenerative Medicines. The distinguished panel including Valerie Dixon of Morgan Stanley, Sean Mackay of Casdin Capital, LLC, and Matthew Hewitt of Charles River Laboratories discussed “Biotech Investing Deal Makers and Breakers”. It was a spirited discussion reflecting the anticipation in the market as we navigate these challenging times. There were strong opinions which founders and anyone tracking the industry should note (link below) however, all panelists agreed:
-Deal numbers and values have returned to pre-COVID days
-Multiples have scaled back from the 20x highs during the exuberance of 2021/2022 and are closer to 5 to +10X for Life Science Industrials depending on the tech and fit
-Founders should not just be thinking about runway over the next few quarters but rather sustained growth over the next few years
-"Dead Cells Don't Cure Cancer" - process technologies and services will always be needed to advance therapies